Doug Williamson

Company: QurAlis Corp.

Job title: Chief Medical Officer

Seminars:

Recovering Misplacing Errors with QRL-201 & QRL-101 to Restore Function & Reduce Disease Burden in ALS 11:00 am

Understanding QRL-201 and QRL-101 mechanisms for restoring STMN2 expression and reducing hyperexcitability induced neurodegeneration in ALS, using FlexASO splicing technology to correct misplacing Unveiling preliminary trial results showcasing QRL-201 efficacy and safety data in humans Identifying potential subgroups that may benefit from more personalized approachesRead more

day: Conference Day Two Workshop B